AIP
HRMY icon

ARS Investment Partners’s Harmony Biosciences HRMY Stock Holding History

ARS Investment Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$622K Sell
17,085
-1,120
-6% -$35.3K 0.03% 117
2026
Q1 		$510K Sell
18,205
-3,000
-14% -$98.4K 0.03% 114
2025
Q4 		$793K Sell
21,205
-250
-1% -$8.22K 0.05% 103
2025
Q3 		$591K Sell
21,455
-2,800
-12% -$96.5K 0.04% 108
2025
Q2 		$766K Sell
24,255
-185
-0.8% -$5.95K 0.06% 105
2025
Q1 		$841K Hold
24,440
– – 0.08% 95
2024
Q4 		$841K Buy
+24,440
New +$840K 0.08% 95

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ARS Investment Partners's HRMY Position: Q2 2026 in Review

ARS Investment Partners reduced its Harmony Biosciences (HRMY) stake by 6.2% in Q2 2026, selling an estimated $35.3K and leaving 17,085 shares worth $622K. The position accounts for 0.03% of the portfolio, ranked #117.

ARS Investment Partners first reported a position in HRMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $841K in Q1 2025. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • ARS Investment Partners held 17,085 shares of Harmony Biosciences worth $622K as of Q2 2026.
  • ARS Investment Partners sold 1,120 Harmony Biosciences shares in Q2 2026, an estimated $35.3K.
  • Harmony Biosciences made up 0.03% of ARS Investment Partners's portfolio in Q2 2026, its #117 holding.
  • ARS Investment Partners first reported a position in Harmony Biosciences in Q4 2024 and has held it in 7 quarters since.
  • ARS Investment Partners's Harmony Biosciences position peaked at $841K in Q1 2025.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on ARS Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.